Upgrade to SI Premium - Free Trial

Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Faga Daniel

April 22, 2026 6:33 PM
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Faga Daniel
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $ 31.12 04/20/2026 D (1) 11,000 (2) 11/25/2031 Common Stock 16,510 $ 0 16,510 D
Employee Stock Option (right to buy) $ 22.8 04/20/2026 A (1) 11,000 (2) 11/25/2031 Common Stock 11,000 $ 0 11,000 D
Employee Stock Option (right to buy) $ 31.12 04/20/2026 D (1) 2,321 (2) 11/25/2031 Common Stock 2,321 $ 0 2,321 D
Employee Stock Option (right to buy) $ 22.8 04/20/2026 A (1) 2,321 (2) 11/25/2031 Common Stock 2,321 $ 0 2,321 D
Employee Stock Option (right to buy) $ 30.44 04/20/2026 D (1) 9,200 (2) 02/09/2032 Common Stock 9,200 $ 0 9,200 D
Employee Stock Option (right to buy) $ 22.31 04/20/2026 A (1) 9,200 (2) 02/09/2032 Common Stock 9,200 $ 0 9,200 D
Employee Stock Option (right to buy) $ 23.23 04/20/2026 D (1) 194,900 (3) 01/05/2033 Common Stock 194,900 $ 0 194,900 D
Employee Stock Option (right to buy) $ 17.02 04/20/2026 A (1) 194,900 (3) 01/05/2033 Common Stock 194,900 $ 0 194,900 D
Employee Stock Option (right to buy) $ 21.19 04/20/2026 D (1) 379,620 (4) 01/02/2034 Common Stock 379,620 $ 0 379,620 D
Employee Stock Option (right to buy) $ 15.53 04/20/2026 A (1) 379,620 (4) 01/02/2034 Common Stock 379,620 $ 0 379,620 D
Employee Stock Option (right to buy) $ 14.83 04/20/2026 D (1) 305,500 (5) 01/06/2035 Common Stock 305,500 $ 0 305,500 D
Employee Stock Option (right to buy) $ 10.87 04/20/2026 A (1) 305,500 (5) 01/06/2035 Common Stock 305,500 $ 0 305,500 D
Employee Stock Option (right to buy) $ 43.91 04/20/2026 D (1) 133,400 (6) 01/06/2036 Common Stock 133,400 $ 0 133,400 D
Employee Stock Option (right to buy) $ 32.17 04/20/2026 A (1) 133,400 (6) 01/06/2036 Common Stock 133,400 $ 0 133,400 D
Explanation of Responses:
1. Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
2. The stock option is fully vested and exercisable.
3. The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
5. The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
6. The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Dan Faga 04/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings